UK Should Look To France To Speed Up Access To Innovative Medicines
Executive Summary
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
You may also be interested in...
Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
Scotland Okays First ILAP Drugs For Reimbursement
The Scottish Medicines Consortium has recommended Gilead’s Trodelvy, Amgen’s Lumykras and Pfizer’s Lorviqua for use on the Scottish National Health Service.
NICE Board Approves Landmark Changes To Increase Flexibility Of Drug Evaluation Methods And Processes In England
Big changes are in store at UK health technology assessment body NICE aimed at improving the way medicines are assessed.